Ingram Micro (INGM) came out with quarterly earnings of $0.96 per share, beating the Zacks Consensus Estimate of $0.9 per share. This compares to earnings of $0.92 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +6.67%. A quarter ago, it was expected that this provider of information technology products and services would post earnings of $0.67 per share when it actually produced earnings of $0.72, delivering a surprise of +7. ...

Pembina Pipeline (PBA) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.5 per share. This compares to earnings of $0.66 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +12.74%. A quarter ago, it was expected that this oil and gas transportation and services company would post earnings of $0.45 per share when it actually produced earnings of $0.31, delivering a surprise of -31.11%. ...

分组1 - Flowco Holdings Inc. reported quarterly earnings of $0.73 per share, significantly exceeding the Zacks Consensus Estimate of $0.24 per share, representing an earnings surprise of +210.64% [1] - The company achieved revenues of $197.21 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 4.05% and showing an increase from $185.99 million year-over-year [2] - Flowco Holdings Inc. has outperformed the S&P 500, with shares increasing by about 18.9% since the beginning of the year compared to the S&P 500's gain of 1.5% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is $0.23 on revenues of $193.16 million, while for the current fiscal year, the estimate is $0.96 on revenues of $802.27 million [7] - The Zacks Industry Rank for Oil and Gas - Integrated - International is currently in the bottom 38% of over 250 Zacks industries, indicating potential challenges for stocks in this sector [8] - Flowco Holdings Inc. has a Zacks Rank of 3 (Hold), suggesting that the stock is expected to perform in line with the market in the near future [6]

分组1 - Diamondback Energy reported quarterly earnings of $1.74 per share, missing the Zacks Consensus Estimate of $1.88 per share, and down from $3.64 per share a year ago, representing an earnings surprise of -7.20% [1] - The company posted revenues of $3.38 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 7.01%, but down from $3.71 billion year-over-year [2] - Diamondback has surpassed consensus EPS estimates three times over the last four quarters and topped consensus revenue estimates four times during the same period [2] 分组2 - The stock has gained approximately 17.1% since the beginning of the year, significantly outperforming the S&P 500's gain of 0.9% [3] - The current consensus EPS estimate for the upcoming quarter is $2.08 on revenues of $3.24 billion, and for the current fiscal year, it is $9.05 on revenues of $13.35 billion [7] - The Zacks Industry Rank for Oil and Gas - Exploration and Production - United States is currently in the bottom 10% of over 250 Zacks industries, indicating potential challenges for the sector [8]

分组1 - Sun Country Airlines reported quarterly earnings of $0.17 per share, exceeding the Zacks Consensus Estimate of $0.13 per share, but down from $0.27 per share a year ago, representing an earnings surprise of +36.00% [1] - The company achieved revenues of $280.96 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 2.71% and increasing from $260.41 million year-over-year [2] - Sun Country Airlines has outperformed the S&P 500 with a share price increase of approximately 34.4% since the beginning of the year, compared to the S&P 500's gain of 0.5% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is $0.70 on revenues of $327.97 million, and for the current fiscal year, it is $1.67 on revenues of $1.22 billion [7] - The Transportation - Airline industry, to which Sun Country Airlines belongs, is currently ranked in the top 19% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Core Insights - Haemonetics reported quarterly earnings of $1.31 per share, exceeding the Zacks Consensus Estimate of $1.27 per share, and up from $1.19 per share a year ago [1] - The company achieved a revenue of $338.97 million for the quarter, surpassing the Zacks Consensus Estimate by 1.44%, although this represents a decline from $348.54 million in the same quarter last year [3] Earnings Performance - The earnings surprise for the recent quarter was +3.15%, following a previous surprise of +13.39% when earnings were $1.27 per share against an expectation of $1.12 per share [2] - Haemonetics has consistently surpassed consensus EPS estimates over the last four quarters [2] Stock Performance and Outlook - Haemonetics shares have declined approximately 17.7% since the beginning of the year, contrasting with a 0.5% gain in the S&P 500 [4] - The current consensus EPS estimate for the upcoming quarter is $1.30, with expected revenues of $334.48 million, and for the current fiscal year, the estimate is $4.93 on $1.32 billion in revenues [8] Industry Context - The Medical - Products industry, to which Haemonetics belongs, is currently ranked in the bottom 29% of over 250 Zacks industries, indicating potential challenges for stock performance [9] - Empirical research suggests that trends in earnings estimate revisions are strongly correlated with near-term stock movements, which may impact Haemonetics' future performance [6]

Core Viewpoint - Boston Scientific reported quarterly earnings of $0.8 per share, exceeding the Zacks Consensus Estimate of $0.78 per share, and showing an increase from $0.7 per share a year ago, indicating a positive earnings surprise of +2.96% [1] Financial Performance - The company achieved revenues of $5.29 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.39%, and up from $4.56 billion year-over-year [2] - Over the last four quarters, Boston Scientific has consistently exceeded consensus EPS estimates and revenue estimates [2] Stock Performance - Boston Scientific shares have declined approximately 3.9% since the beginning of the year, while the S&P 500 has gained 1.1% [3] - The stock's immediate price movement will largely depend on management's commentary during the earnings call [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.79, with expected revenues of $5.2 billion, and for the current fiscal year, the EPS estimate is $3.45 on revenues of $22.32 billion [7] - The estimate revisions trend for Boston Scientific was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Products industry, to which Boston Scientific belongs, is currently ranked in the bottom 34% of over 250 Zacks industries, suggesting potential challenges ahead [8] - The performance of Boston Scientific's stock may be influenced by the overall outlook for the industry [8]

分组1 - Sonos reported quarterly earnings of $0.93 per share, exceeding the Zacks Consensus Estimate of $0.81 per share, and up from $0.64 per share a year ago, representing an earnings surprise of +14.82% [1] - The company posted revenues of $545.66 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 1.29%, although this is a decrease from year-ago revenues of $550.86 million [2] - Sonos shares have declined approximately 15.5% since the beginning of the year, contrasting with the S&P 500's gain of 1.9% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is $0.01 on revenues of $266.53 million, and for the current fiscal year, it is $1.01 on revenues of $1.48 billion [7] - The Audio Video Production industry, to which Sonos belongs, is currently ranked in the top 12% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

分组1 - Otis Worldwide reported quarterly earnings of $1.03 per share, matching the Zacks Consensus Estimate, and showing an increase from $0.93 per share a year ago, with an earnings surprise of -0.38% [1] - The company posted revenues of $3.8 billion for the quarter ended December 2025, which was 2.72% below the Zacks Consensus Estimate, and an increase from $3.68 billion year-over-year [2] - Over the last four quarters, Otis Worldwide has surpassed consensus EPS estimates three times, but has only topped revenue estimates once [2] 分组2 - The stock has gained approximately 3.7% since the beginning of the year, outperforming the S&P 500, which has gained 1.9% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the upcoming quarter is $0.99 on revenues of $3.53 billion, and for the current fiscal year, it is $4.37 on revenues of $15.19 billion [7] 分组3 - The Zacks Industry Rank places Manufacturing - General Industrial in the top 33% of over 250 Zacks industries, indicating that the industry outlook can significantly impact stock performance [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors or through tools like the Zacks Rank [5][6]

Core Viewpoint - Boston Scientific (BSX) is showing potential as a stock pick due to its recent technical performance and positive earnings estimate revisions [1][3]. Technical Analysis - BSX has surpassed the 50-day moving average, indicating a short-term bullish trend [1]. - The stock has increased by 5.7% over the past four weeks, suggesting upward momentum [2]. Earnings Estimates - There have been no downward revisions for BSX's earnings estimates in the past two months, with one upward revision noted [3]. - The consensus estimate for BSX has also increased, reinforcing the bullish outlook for the stock [3]. Market Position - BSX is currently rated as a Zacks Rank 2 (Buy), indicating strong potential for continued growth [2].